• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics

by Fred Pennic 07/10/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics

What You Should Know:

– Repurpose.AI, has partnered with Scripps Research to discover drug candidates that may be repurposed to treat COVID-19. 

– The partnership will leverage Repurpose.AI’s ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover drug candidates to treat COVID-19. 


Scripps Research is teaming up with Repurpose.AI, an AI drug discovery company to develop COVID-19 therapeutics. The partnership will leverage Repurpose.AI’s ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover drug candidates to treat COVID-19. Previously, the company has successfully utilized the platform to discover REP-001, REP-002, and REP-003 – three Phase II/III ready small molecule assets for the treatment of gastric, neurological, and weight disorders, respectively.

Partnership Details

Scripps Research scientists together with Calibr, its drug development division, will leverage its COVID-19 screening models and commitment to drug repurposing as part of the partnership. Calibr previously established the ReFRAME collection, the world’s leading collection of known drugs, comprising over 14,000 compounds that have been approved by the FDA for other diseases or have been extensively tested for human safety, which it is bringing to bear on the current pandemic. The collaborative work with Repurpose.AI will augment this effort by characterizing compounds not identified to date using conventional repurposed drug screening approaches.

 “We could not be more excited about our partnership with Scripps Research and Calibr. Like Repurpose.AI, Calibr is committed to ending the scourge of the global COVID-19 pandemic. Our goal is to move therapeutics from the computer to the clinic in a fraction of the time typically required to discover and bring new drugs to market and alleviate the suffering of patients afflicted by COVID-19. Creating therapeutics to treat COVID-19 also allows the global community to go back to work and for children to go back to school. Repurpose.AI and Calibr are committed to doing our part to ensure that happens sooner rather than later,” said Dr. Daniel Haders II, Ph.D., Executive Chairman at Repurpose.AI.

AI-Driven Drug Discovery

Repurpose.AI, a Nex Cubed digital health portfolio company, has harnessed the predictive prowess of artificial intelligence and machine learning with its ActivPred AI Drug Discovery Platform to discover drugs that may be repurposed to serve as therapeutics to treat patients suffering from COVID-19. The drugs that Repurpose.AI discovers for COVID-19 can enter clinical trials in as little as several months.

Repurpose.AI’s Drug Library

Repurpose.AI’s Drug Library is comprised of approximately 4,000 drug compounds that have been approved for commercial use by the U.S. FDA, or similar agencies, and 20,000+ drug compounds that are known to have successfully navigated a Phase I (human safety) clinical trial. All drugs have a full pre-clinical program, an existing or legacy supply chain, and are known to be safe and well-tolerated in humans.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Artificial Intelligence, Clinical Trial, Clinical Trials, Coronavirus (COVID-19), digital health, Digital Therapeutics, Drug Discovery, FDA, Machine Learning, Scripps

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |